Provided by Tiger Trade Technology Pte. Ltd.

Alumis Inc.

9.80
0.0000
Volume:2.08M
Turnover:20.85M
Market Cap:1.26B
PE:-2.58
High:10.55
Open:10.55
Low:9.65
Close:9.80
52wk High:31.35
52wk Low:3.76
Shares:129.00M
Float Shares:104.00M
Volume Ratio:0.67
T/O Rate:2.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8005
EPS(LYR):-2.8616
ROE:-93.65%
ROA:-45.34%
PB:2.80
PE(LYR):-3.42

Loading ...

Alumis Q1 Loss Narrows, Revenue Falls; Shares Down Pre-Bell

MT Newswires Live
·
May 15

HC Wainwright Downgrades Alumis to Neutral From Buy

MT Newswires Live
·
May 15

Alumis price target raised to $34 from $32 at Guggenheim

TIPRANKS
·
May 15

Alumis Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
May 15

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 15

Alumis Inc. (ALMS) Gets a Buy from Wells Fargo

TIPRANKS
·
May 15

Alumis Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 15

Alumis Q1 EPS $(0.74) Beats $(0.77) Estimate, Sales $1.741M Miss $2.767M Estimate

Benzinga Earnings
·
May 15

Alumis Q1 revenue drops, net loss narrows after trial completion

Reuters
·
May 15

Alumis Q1 FY26 net loss narrows 6% to $93.05 million; revenue drops 90% to $1.74 million

Reuters
·
May 15

Alumis posts corporate deck on next-generation TYK2 inhibitors for immune-mediated diseases

Reuters
·
May 15

BRIEF-Alumis Q1 Operating Expenses USD 100.15 Million

Reuters
·
May 15

Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements

THOMSON REUTERS
·
May 15

Why Is Alumis Stock Falling Monday?

Benzinga_recent_news
·
Mar 31

Alumis falls -16.1%

TIPRANKS
·
Mar 31

Envu’s Compelling Efficacy and Superior Safety Profile Support Buy Rating on ALMS

TIPRANKS
·
Mar 30

Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James

TIPRANKS
·
Mar 30

Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer Says

MT Newswires Live
·
Mar 30

Oppenheimer Adjusts Alumis Price Target to $55 From $50, Maintains Outperform Rating

MT Newswires Live
·
Mar 30

Alumis Inc. : Oppenheimer Raises Target Price to $55 From $50

THOMSON REUTERS
·
Mar 30